Cargando…

The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology

INTRODUCTION: Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and sugges...

Descripción completa

Detalles Bibliográficos
Autores principales: Handen, Benjamin L., Lott, Ira T., Christian, Bradley T., Schupf, Nicole, OBryant, Sid, Mapstone, Mark, Fagan, Anne M., Lee, Joseph H., Tudorascu, Dana, Wang, Mei‐Cheng, Head, Elizabeth, Klunk, William, Ances, Beau, Lai, Florence, Zaman, Shahid, Krinsky‐McHale, Sharon, Brickman, Adam M., Rosas, H. Diana, Cohen, Annie, Andrews, Howard, Hartley, Sigan, Silverman, Wayne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396809/
https://www.ncbi.nlm.nih.gov/pubmed/32775597
http://dx.doi.org/10.1002/dad2.12065
_version_ 1783565652806598656
author Handen, Benjamin L.
Lott, Ira T.
Christian, Bradley T.
Schupf, Nicole
OBryant, Sid
Mapstone, Mark
Fagan, Anne M.
Lee, Joseph H.
Tudorascu, Dana
Wang, Mei‐Cheng
Head, Elizabeth
Klunk, William
Ances, Beau
Lai, Florence
Zaman, Shahid
Krinsky‐McHale, Sharon
Brickman, Adam M.
Rosas, H. Diana
Cohen, Annie
Andrews, Howard
Hartley, Sigan
Silverman, Wayne
author_facet Handen, Benjamin L.
Lott, Ira T.
Christian, Bradley T.
Schupf, Nicole
OBryant, Sid
Mapstone, Mark
Fagan, Anne M.
Lee, Joseph H.
Tudorascu, Dana
Wang, Mei‐Cheng
Head, Elizabeth
Klunk, William
Ances, Beau
Lai, Florence
Zaman, Shahid
Krinsky‐McHale, Sharon
Brickman, Adam M.
Rosas, H. Diana
Cohen, Annie
Andrews, Howard
Hartley, Sigan
Silverman, Wayne
author_sort Handen, Benjamin L.
collection PubMed
description INTRODUCTION: Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments. METHODS: We describe the development of a multi‐center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid‐based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16‐month intervals), as well as genetic modifiers of AD risk and progression. RESULTS: Approximately 400 individuals will be enrolled in the study (more than 370 to date). The methodological approach from the administrative, clinical, neuroimaging, omics, neuropathology, and statistical cores is provided. DISCUSSION: This represents the largest U.S.‐based, multi‐site, biomarker initiative of AD in DS. Findings can inform other multidisciplinary networks studying AD in the general population.
format Online
Article
Text
id pubmed-7396809
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73968092020-08-06 The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology Handen, Benjamin L. Lott, Ira T. Christian, Bradley T. Schupf, Nicole OBryant, Sid Mapstone, Mark Fagan, Anne M. Lee, Joseph H. Tudorascu, Dana Wang, Mei‐Cheng Head, Elizabeth Klunk, William Ances, Beau Lai, Florence Zaman, Shahid Krinsky‐McHale, Sharon Brickman, Adam M. Rosas, H. Diana Cohen, Annie Andrews, Howard Hartley, Sigan Silverman, Wayne Alzheimers Dement (Amst) Review Articles INTRODUCTION: Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments. METHODS: We describe the development of a multi‐center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid‐based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16‐month intervals), as well as genetic modifiers of AD risk and progression. RESULTS: Approximately 400 individuals will be enrolled in the study (more than 370 to date). The methodological approach from the administrative, clinical, neuroimaging, omics, neuropathology, and statistical cores is provided. DISCUSSION: This represents the largest U.S.‐based, multi‐site, biomarker initiative of AD in DS. Findings can inform other multidisciplinary networks studying AD in the general population. John Wiley and Sons Inc. 2020-08-03 /pmc/articles/PMC7396809/ /pubmed/32775597 http://dx.doi.org/10.1002/dad2.12065 Text en © 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Handen, Benjamin L.
Lott, Ira T.
Christian, Bradley T.
Schupf, Nicole
OBryant, Sid
Mapstone, Mark
Fagan, Anne M.
Lee, Joseph H.
Tudorascu, Dana
Wang, Mei‐Cheng
Head, Elizabeth
Klunk, William
Ances, Beau
Lai, Florence
Zaman, Shahid
Krinsky‐McHale, Sharon
Brickman, Adam M.
Rosas, H. Diana
Cohen, Annie
Andrews, Howard
Hartley, Sigan
Silverman, Wayne
The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology
title The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology
title_full The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology
title_fullStr The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology
title_full_unstemmed The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology
title_short The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology
title_sort alzheimer's biomarker consortium‐down syndrome: rationale and methodology
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396809/
https://www.ncbi.nlm.nih.gov/pubmed/32775597
http://dx.doi.org/10.1002/dad2.12065
work_keys_str_mv AT handenbenjaminl thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT lottirat thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT christianbradleyt thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT schupfnicole thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT obryantsid thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT mapstonemark thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT faganannem thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT leejosephh thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT tudorascudana thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT wangmeicheng thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT headelizabeth thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT klunkwilliam thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT ancesbeau thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT laiflorence thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT zamanshahid thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT krinskymchalesharon thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT brickmanadamm thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT rosashdiana thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT cohenannie thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT andrewshoward thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT hartleysigan thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT silvermanwayne thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT thealzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT handenbenjaminl alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT lottirat alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT christianbradleyt alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT schupfnicole alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT obryantsid alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT mapstonemark alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT faganannem alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT leejosephh alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT tudorascudana alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT wangmeicheng alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT headelizabeth alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT klunkwilliam alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT ancesbeau alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT laiflorence alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT zamanshahid alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT krinskymchalesharon alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT brickmanadamm alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT rosashdiana alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT cohenannie alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT andrewshoward alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT hartleysigan alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT silvermanwayne alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology
AT alzheimersbiomarkerconsortiumdownsyndromerationaleandmethodology